Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Choroid plexus cell replacement therapy - Living Cell Technologies

Drug Profile

Choroid plexus cell replacement therapy - Living Cell Technologies

Alternative Names: Neurological disorders cell therapy - Living Cell Technologies; NeurotrophinCell; NTCELL

Latest Information Update: 08 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Living Cell Technologies
  • Developer Auckland UniServices; Living Cell Technologies; University of Auckland
  • Class Antidementias; Antiparkinsonians; Cell therapies; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Cell replacements; Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease
  • Preclinical Hearing loss; Huntington's disease; Wounds
  • Research Alzheimer's disease; Retinal disorders
  • No development reported Osteoarthritis; Osteoporosis; Spinal cord injuries; Stroke

Most Recent Events

  • 04 Jan 2018 Development is underway for Hearing loss, Retinal disorders and Huntington's disease (9230315; 9230035)
  • 10 Nov 2017 Adverse events and efficacy data from a phase II trial in Parkinson's disease released by Living Cell Technologies
  • 07 Nov 2017 Living Cell Technologies Limited files a provisional patent for pericyte protective agents
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top